Compare Abeona Therapeutics Inc (ABEO) vs Progressive Corp (PGR) Price & Performance

ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.

The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.

Progressive (PGR) trades at $213.95, down 0.64% on the day, with a bullish technical outlook supported by moving averages. The company shows strong fundamental performance with revenue growing from $49.6B in 2022 to $87.6B in 2025 and net income reaching $11.3B. Recent Q2 2026 earnings beat expectations at $4.85 per share, though the combined ratio widened to 87.1%, indicating potential growth trade-offs. Analyst consensus price target stands at $231.20 with 37% buy ratings.

PGR presents a compelling investment case with reasonable valuation (P/E 10.65) and strong profitability (ROE 34.94%), though investors face risks from competitive pressures and potential margin compression as the company expands its bundled insurance offerings. The stock offers 8% upside to consensus target with balanced risk-reward profile.